Evidence map›Paper›PMID 31768569›Full record

ReviewIntensive care medicine2020

ECLS-associated infections in adults: what we know and what we don't yet know.

Darryl Abrams, Giacomo Grasselli, Matthieu Schmidt, Thomas Mueller, Daniel Brodie

Open access · bronzeAbstract readReview
In one paragraph

Review in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Infections in Patients with Mechanical Circulatory Support.Infectious disease clinics of North America · 2024
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Interaction of ceftazidime and clindamycin with extracorporeal life support.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 4 countries.

Darryl AbramsColumbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, NY, USA.ORCID 0000-0001-9073-3897
Giacomo GrasselliDepartment of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Matthieu SchmidtSorbonne Université, INSERM, UMRS_1166-ICAN, Paris, France.
Thomas MuellerDepartment of Internal Medicine II, University Hospital of Regensburg, Regensburg, Germany.
Daniel BrodieColumbia University College of Physicians and Surgeons, New York-Presbyterian Hospital, New York, NY, USA. hdb5@cumc.columbia.edu.
NewYork–Presbyterian Hospital · USInserm · FRUniversity Hospital Regensburg · DEUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracorporeal life support (ECLS) is increasingly used in the management of patients with severe cardiopulmonary disease. Infections are frequently the etiologies underlying the respiratory, and occasionally cardiac, failure that necessitates ECLS. Just as importantly, infections are among the most commonly reported adverse events during ECLS. Infections in this setting may be the sequelae of prolonged critical illness or of underlying immune dysregulation; they may be hospital-acquired infections, and they may or may not be attributable to the presence of ECLS itself, the latter being an aspect that can be difficult to determine. Current registry data and evidence from the literature offer some insights, but also leave open many questions regarding the nature and significance of infections reported both before and during ECLS, including the question of any causal link between ECLS and the development of infections. An ongoing lack of consistency in the identification, diagnosis, management, and prevention of infections during ECLS is limiting our ability to interpret literature data and thus highlighting the need for more rigorous investigation and standardization of definitions. This review aims to characterize the current understanding of infections associated with the use of ECLS, taking into account data from the updated Extracorporeal Life Support Organization Registry, which provides important context for understanding the epidemiology and outcomes of these patients.

Indexed as

Cross InfectionExtracorporeal Membrane OxygenationHumansRegistriesRisk FactorsSeverity of Illness IndexComplicationsECLSECMOELSO registryInfectionsNosocomial

Identifiers

PMID31768569
PMCPMC7222121
OpenAlexW2991480147

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.